Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 3/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4949504 | 0.85 | ACHE (0.42) | ACHECES2CES1NPC1RAB9A | |
| SCHEMBL3162903 | 0.85 | PTPN1 (0.57) | CES2CES1NPC1RAB9AMAOB | |
| SCHEMBL28037289 | 0.85 | CES2 (0.41) | CES2CES1NPC1RAB9AMAOB | |
| SCHEMBL31149832 | 0.85 | PTPN1 (0.57) | CES2CES1NPC1RAB9AMAOB | |
| SCHEMBL12430465 | 0.84 | ACHE (0.44) | ACHECES2CES1PTPN1GSK3B | |
| SCHEMBL3013333 | 0.83 | MAPT (0.50) | NPC1RAB9AALDH1A1 | |
| SCHEMBL671907 | 0.82 | CES2 (0.61) | ACHECES2CES1NPC1RAB9A | |
| SCHEMBL2555281 | 0.80 | MAOB (0.40) | CES2CES1NPC1RAB9AMAOB | |
| SCHEMBL5378544 | 0.80 | KMT2A (0.49) | NPC1RAB9AALDH1A1 | |
| SCHEMBL30817696 | 0.79 | ALDH1A1 (0.52) | CES2CES1NPC1RAB9AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2585440-A1 | 3-AMINO-5,6-DIHYDRO-1H-PYRAZIN-2-ONE DERIVATIVES USEFUL FOR THE TREATEMENT OF ALZHEIMER'S DISEASE AND OTHER FORMS OF DEMENTIA | Janssen Pharmaceutica, N.V. (BE) | 2013-05-01 | — | — | EP | disclosed |
| US-20130102618-A1 | 3-AMINO-5,6-DIHYDRO-1H-PYRAZIN-2-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER FORMS OF DEMENTIA | JANSSEN PHARMACEUTICA NV (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2012095781-A1 | INDAZOLE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-07-19 | — | — | WO | disclosed |
| WO-2012000933-A1 | 3-AMINO-5,6-DIHYDRO-1H-PYRAZIN-2-ONE DERIVATIVES USEFUL FOR THE TREATEMENT OF ALZHEIMER'S DISEASE AND OTHER FORMS OF DEMENTIA | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102618-A1 | 3-AMINO-5,6-DIHYDRO-1H-PYRAZIN-2-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER FORMS OF DEMENTIA | BACE2, BACE1, PSEN2 | ACHE 93/4885CES2 2143/4885CES1 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.